伐尼克兰、安非他酮、尼古丁贴片与安慰剂对当前或既往重性抑郁障碍患者戒烟效果的影响:双盲随机安慰剂对照试验的二次分析
该研究为双盲随机安慰剂对照试验的二次分析,纳入18-75岁既往重性抑郁障碍(N=2174)、当前重性抑郁障碍(N=451)及无精神障碍(N=4028)的吸烟者,比较12周伐尼克兰、安非他酮、尼古丁贴片或安慰剂加简短咨询的安全性与疗效。结果显示各药物在抑郁障碍队列中神经精神不良事件风险无差异;当前重性抑郁障碍队列中尼古丁贴片和安非他酮不优于安慰剂,伐尼克兰优于安慰剂和尼古丁贴片;作者认为伐尼克兰加咨询可能是既往或当前重性抑郁障碍患者的最佳治疗。
要点
- 各药物在既往或当前重性抑郁障碍队列中神经精神不良事件风险无差异。
- 当前重性抑郁障碍队列中,尼古丁贴片和安非他酮不优于安慰剂。
- 伐尼克兰加咨询可能对既往或当前重性抑郁障碍患者最有效。
核心结论
- 所有药物在既往和当前重性抑郁障碍队列中总体安全。
- 尼古丁贴片和安非他酮对当前重性抑郁障碍患者不优于安慰剂。
- 伐尼克兰加咨询可能对既往或当前重性抑郁障碍患者是最佳治疗,因其疗效更好、不良事件风险相似,且对当前抑郁者在戒烟期间焦虑和抑郁有减轻。
研究设计与样本
- 随机双盲试验的二次分析,为期12周治疗加12周评估。
- 参与者年龄18-75岁,包括既往重性抑郁障碍(N=2174)、当前重性抑郁障碍(N=451)及无精神障碍(N=4028)者。
- 干预为12周药物治疗(安慰剂、尼古丁贴片、安非他酮或伐尼克兰)加简短咨询。
主要发现
- 在所有6653名参与者中,既往重性抑郁障碍、当前重性抑郁障碍及无精神障碍队列内神经精神不良事件风险不因药物而异。
- 重性抑郁障碍队列相比无精神障碍队列神经精神不良事件风险差异更高(p<0.001):既往重性抑郁障碍队列风险差异=-0.03,95%CI=-0.05,-0.02;当前重性抑郁障碍队列风险差异=-0.02,95%CI=-0.05,0.00。
- 既往重性抑郁障碍队列中,相比安慰剂的比值比:伐尼克兰3.0(95%CI=2.0,4.5),安非他酮2.1(95%CI=1.6,2.7),尼古丁贴片2.1(95%CI=1.4,3.2)。
- 当前重性抑郁障碍队列中,伐尼克兰与安慰剂不同(比值比=2.67,95%CI=1.2,6.15),与尼古丁贴片不同(比值比=2.93,95%CI=1.2,7.2)。
关键数值与推荐
- 主要安全性结局为发生一次或以上中度至重度神经精神不良事件。
- 疗效评估为第9-12周生化验证的持续戒断。
临床怎么用
- 作者认为伐尼克兰加咨询可能是既往或当前重性抑郁障碍患者的最佳治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD). METHODS: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling. The primary safety outcome was occurrence of one or more moderate to severe neuropsychiatric adverse events. Efficacy was assessed as biochemically verified continuous abstinence during weeks 9-12. RESULTS: Among all 6,653 participants, the risk of neuropsychiatric adverse events did not differ by medication within the past-MDD, current-MDD, or nonpsychiatric cohorts. The MDD cohorts had higher risk difference (p<0.001) for neuropsychiatric adverse events compared with the nonpsychiatric cohort (past-MDD cohort, risk difference=-0.03, 95% CI=-0.05, -0.02; current-MDD cohort, risk difference=-0.02, 95% CI=-0.05, 0.00). Within the past-MDD cohort, the odds ratios compared with placebo were 3.0 (95% CI=2.0, 4.5) for varenicline, 2.1 (95% CI=1.6, 2.7) for bupropion, and 2.1 (95% CI=1.4, 3.2) for NRT. Within the current-MDD cohort, varenicline differed from placebo (odds ratio=2.67, 95% CI=1.2, 6.15) and NRT (odds ratio=2.93, 95% CI=1.2, 7.2). CONCLUSIONS: All medications were generally safe in both MDD cohorts. NRT and bupropion were not more effective than placebo for those with current MDD. Varenicline plus counseling may be the best treatment for individuals with past or current MDD, given its greater efficacy, similar risk of adverse events, and, for those with current depression, reductions in anxiety and depression while trying to quit smoking.
引用
- Kypriotakis G, Cinciripini PM, Green CE, et al. Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2024. PMID: 39659160. doi:10.1176/appi.ajp.20230855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。